ClinicalTrials.gg
CompletedNCT01028079Updated Dec 9, 2009

Placebo and Active Controlled, Double Dummy Study to Prove Efficacy of Aspirin in Treatment of Acute Low Back Pain

A Phase 3 interventional study of Acetylsalicylic Acid (Aspirin, BAYE4465) and Ibuprofen in Low Back Pain, sponsored by Bayer. Completed at 13 sites in 2 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2009-12-09.

Sponsored by Bayer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
338
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 59 studies in Low Back Pain with a site in Germany — 5 open to participants now, 8 under way, 3 of them phase 3. Low Back Pain · Germany.

Enrollment
14th of 54
338 · median 128
Started
2005
the only one that year
Phase 3
14 of 59
2 open now
Registered
12th of 59
by date
Lead sponsor
1 of 59
Bayer

Among the 59 studies in Low Back Pain with a site in Germany, this one is the 14th largest by enrollment of the 54 interventional ones that give a count, is the only one that started in 2005, is one of 14 in phase 3, and was the 12th registered.

Low Back Pain

2,926 studies on the registry are indexed under Low Back Pain; 579 are open to participants now.

Browse Low Back Pain studies →

Open to participants now

5 of the 59 studies in Low Back Pain with a site in Germany are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 332 Low Back Pain studies recruiting now, 92 (28%) set no upper age limit and 210 (63%) stop at 75 or younger; 8 take children under 18; 46 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Low Back Pain with a site in Germany, or all of them as a file.
02

Study summary

The purpose of this study is to determine the efficacy and safety of 1000 mg Aspirin (the study medication) by comparing it to placebo (the control group without active substance) or 400 mg Ibuprofen (the control group with an active substance) in treating the symptoms of back pain. The study is designed to develop a treatment method against back pain which will have more advantages for patients than the methods that are currently available.

03

Conditions studied

  • Low Back Pain

Keywords

  • Back Pain
  • Acute low back pain
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ambulatory male or female, 18 to 70 years of age
  • ranging in-between 18 and 30 kg/m²
  • Normal blood pressure
  • Patients suffering from low back pain
  • Low back pain, localized below the costal margin and above the inferior gluteal folds, either as acute low back pain, or as chronic or intermittent low back pain

Exclusion criteria

Exclusion Criteria:

  • to acetylsalicylic, salicylates, or other Non Steroidal Anti-inflammatory drugs
  • Serious physical illness especially uncontrolled disorders of kidney, liver, lung, heart or brain function, neurological disorders or severe chronic or terminal disease
  • Pregnancy or lactation period
  • Abuse of alcohol or addictive substances
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
338 participants (actual)

Study arms

  • Active comparator
    Arm 2

    Drug: Ibuprofen

  • Placebo comparator
    Arm 3

    Drug: Placebo

  • Experimental
    Arm 1

    Drug: Acetylsalicylic Acid (Aspirin, BAYE4465)

Interventions

  • Aspirin 1000 mg (solid dose caplet) to be given three times daily as for 2 consecutive days (48 hours), followed by Aspirin 1000 mg (solid dose caplet) to be taken as per need, but not more than three times daily for the following 3 days (72 hours). Total treatment period has not to exceed 5 days and total daily dose has not to exceed 3000 mg Aspirin.

  • Ibuprofen 400 mg caplet to be given three times a day as for 2 consecutive days (48 hours), followed by ibuprofen 400 mg caplet to be given as per need, but not more than three times a day for the following 3 days (72 hours). Total treatment period has not to exceed 5 days and total daily dose has not to exceed 1200 mg ibuprofen.

  • DrugPlacebo

    Placebo (two placebos: Placebo Aspirin and Placebo Ibuprofen) to be given three times a day for a maximum of 5 consecutive days in the same regimen as for Experimental Drug and Active Comparator.

06

What researchers measure

Primary outcomes

  1. Area under the curve of the baseline adjusted pain intensity curve over the initial 48 hours (AUC-PI0-48hours) after first dosing

    Time frame: 48 hours

Secondary outcomes

  1. Total pain relief 6, 72, 96 and 120 hours after first dosing

    Time frame: 6, 72, 96 and 120 hours

  2. Pain intensity relief over initial 6 hours

    Time frame: 6 hours

  3. Pain intensity difference after 48, 72, 96 and 120 hours after first dosing

    Time frame: 48, 72, 96 and 120 hours

  4. Overall efficacy after 48, 72, 96 and 120 hours after first dosing

    Time frame: 48, 72, 96 and 120 hours

  5. Total dose used over 5 days

    Time frame: 5 days

  6. Time till use of rescue medication

    Time frame: 5 days

  7. Safety - assessment of adverse events

    Time frame: 5 days

07

Study locations

13 sites
  • Bad Lippspringe, 33175, Germany
  • Beckum, 59269, Germany
  • Einbeck, 37574, Germany
  • Hamburg, 20148, Germany
  • Hamburg, 20459, Germany
  • Hamburg, 21031, Germany
  • Hamburg, 22177, Germany
  • Hannover, 30519, Germany
  • Künzing, 94550, Germany
  • Straßkirchen, 94342, Germany
  • Fowey, PL23 1DT, United Kingdom
  • Saltash, PL12 6DL, United Kingdom
  • Sheffield, S3 9DA, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2005 and a completion of Dec 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 8, 2009
First posted
Dec 9, 2009
Start
Nov 2005
CompletionActual
Dec 2006
Last update
Dec 9, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 9, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01028079
Lead sponsor
Bayer
First posted
Dec 9, 2009
Start date
Nov 2005
Completion
Dec 2006
Last update
Dec 9, 2009

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aspirin

Start the discussion